Nelfinavir. A review of its therapeutic efficacy in HIV infection

Drugs

Volumn 56, Issue 1, 1998, Pages 147-167

  Jarvis, Blair ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; KETOCONAZOLE; NELFINAVIR; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ASTHENIA; CODON; DIARRHEA; DRUG METABOLISM; DRUG RESISTANCE; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NAUSEA; RASH; REVIEW; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HIV; HIV INFECTIONS; HUMANS; NELFINAVIR;

EID: 0031821459     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856010-00013     Document Type: Review

References (98)

1. Molla A, Japour A. HIV protease inhibitors. Curr Opin Infect Dis 1997 Dec; 10: 491-5
2. Flexner C. HIV-Protease Inhibitors. N Engl J Med 1998; 338: 1281-92
3. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997 Mar; 32: 194-209
4. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998 Mar 26; 338 (13): 853-60
5. Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998; 12: 613-8
6. Perry CM, Benfield P, Breckenridge A, et al. Nelfinavir. Drugs 1997; 54 (1): 81-8
7. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996 Feb; 40: 292-7
8. Kaldor SW, Kalish VJ, Davies II JF, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997 Nov 21; 40: 3979-85
9. Rachlis AR, Zarowny DP, Canadian HIV Trials Network Antirectroviral Working Group. Guidelines for antiretroviral therapy for HIV infection. Can Med Assoc J 1998 Feb; 158 (4): 496-505
10. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997 Jun 25; 277: 1962-9
11. Gazzard BG, Moyle GJ, Weber J, et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997 Apr 12; 349: 1086-92
12. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998; 47 (No. RR-4): 1-45
13. Patick AK, Boritzki TJ, Bloom LA. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother 1997 Oct; 41: 2159-64
14. Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997 Nov; 36: 91-7
15. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saqiunavir and other HIV protease inhibitors: theory and practice. AIDS 1998; 12: 453-60
16. Patick AK, Duran M, Cao Y, et al. HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir are not cross-resistant to other protease inhibitors [abstract]. AIDS 1996 Nov; 10 Suppl. 2: S18
17. Maschera B, Darby G, Palu G, et al. Human immunodeficiency virus - mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem 1996 Dec 27; 271: 33231-5
18. Kravcik S, Farnsworth A, Patick A, et al. Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 394c
19. Markowitz M, Cao Y, Hurley A, et al. Virologic and immunologic response to triple therapy with nelfinavir in combination with AZT/3TC in 12 antiretroviral naive HIV-infected subjects at 20 months [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb:371
20. Tebas P, Kane E, Klebert M, et al. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb
21. Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Expert Opin Invest Drug 1998; 7 (3): 413-26
22. Birch C. On the issue of cross-resistance between protease inhibitors. AIDS 1998; 12: 680-1
23. Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates [abstract no. 395]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998
24. Ballard C, Toerner JG, Colwell B, et al. Early CD4, viral load, and quality of life response to salvage treatment with nelfinavir: the UCSD Owen Clinic nelfinavir expanded access experience [abstract no 1-192]. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 1997 Sep 28-Oct 1
25. Sampson MS, Barr MR, Torres RA, et al. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Addendum 1997 Sep 28: 9
26. Gallant JE, Hall C, Barnett S, et al. Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen [abstract no. 427]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb
27. Kerr BM, Yuen GJ, Sandoval T, et al. The pharmacokinetics (PK) of nelfinavir administered alone and with ketoconazole (K) in healthy volunteers [abstract]. 98th American Society for Clinical Pharmacology and Therapeutics 1997 Mar 5: 147
28. Yuen GJ, Anderson R, Sandoval T, et al. The pharmacokinetics (PK) of nelfinavir (N) administered alone and with rifampin (RIF) in healthy volunteers [abstract]. 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, USA, 1997 Mar 5: 147
29. Quart BD, Chapman SK, Peterkin J, et al. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 - a novel HIV protease inhibitor [abstract]. 2nd National Conference on Human Retroviruses and Related Infections 1995 Jan 29: 167
30. Pedneault L, Elion R, Adler M, et al. A pilot study of safety and antiviral activity of the combination of stavudine, didanosine and nelfinavir in HIV-infected subjects [abstract]. AIDS 1996 Nov; 10 Suppl. 2: 17
31. Petersen A, Johnson M, Clendenninn N, et al. Nelfinavir Study 542: Comparison of BID and TID dosing of Nelfinavir (NFV) in combination with stavudine (d4T) and lamivudine (3TC): an interim look [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 Feb 1-5
32. Zhang K, Wu E, Patick A, et al. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: quantitation by LC-MS/MS and antiviral activities [abstract]. 6th ISSX Meeting, Gottenburg, Sweden, 1997 Jun 30: 128
33. Krogstad P, Wiznia A, Luzuriaga K, et al. Evidence of potent antiviral activity in a phase I/II study of nelfinavir mesylate (Viracept) in HIV infected children [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 270
34. Agouron Pharmaceuticals Inc, La Jolla USA, Viracept prescribing information. 1998
35. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-I protease inhibitors. J Clin Invest 1988 Jan 15; 101: 289-94
36. Krogstad P, Kerr B, Anderson R, et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22-26; Washington, DC
37. Wu EY, Sandoval TM, Lee CA, et al. In vitro metabolism studies with the HIV-1 protease inhibitor. Viracept (AG1343) [abstract]. 7th ISSX Meeting, San Diego, California 1996 Oct 20; 10: 326
38. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients [abstract]. Fourth Conference on Retroviruses and Opportunistic Infections Washington, DC 1997 Jan: 389
39. Gallicano K, Sahai J, Kravcik S, et al. Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV-HGC) in HIV+ patients [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 Feb 1-5
40. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997 Dec; 11: 117-20
41. Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 345
42. National AIDS Treatment Advocacy Project. NATAP reports, January 1998, volume 1, number 3-4 [on line] [Accessed 1998, May 27, pages 15-16]. National AIDS Treatment Advocacy Project; 1998. May 5. Available from: URL: http://www.natap.org/reports/report3.html
43. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 349
44. Data on file. Agouron Pharmaceuticals, Inc. La Jolla Ca. USA
45. Skowron G, Leoung G, Dusek A, et al. Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): preliminary safety, activity and pharmacokinetic (PK) interactions [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 350
46. Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb
47. Freimuth W, Peaks S, Slater L, et al. An open-label randomised study of Rescriptor (delavirdine mesylate. DLV). plus nelfinavir (NFV), didanosine (ddl), and stavudine (D4T) in quadruple treatment regimens in HIV-1 infected individuals [abstract]. Can J Infect Dis 1998 March/April: 9 Suppl. A: 64A
48. Gathe JJ, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine (D4T) vs. stavudine (D4T) alone [abstract]. 11th International Conference on AIDS 1996 Jul 7; 1: 25
49. Clendeninn N, Quart B, Anderson R, et al. Analysis of long-term virologic data from the Viracept (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 372
50. Clumeck N, AVANTI 3 Study Group. A randomised double blind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in anti-retroviral naive patients [abstract]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 8
51. Pedneault L, Elion R, Adler M, et al. Stavudine (d4T). didanosine (ddl), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study. 4th International Conference on Retroviruses and Opportunistic Infections, 1997 Jan 22-26; Washington, DC
52. Sension M, Elion R, Farthing C, et al. Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept (nelfinavir mesylate) combined with NRTI's in HIV-infected treatment-naive patients [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 387a
53. Gallant J et al. Phase II study of ritonavir-nelfinavir combination therapy: an update [abstract]. 12th World AIDS Conference, Geneva Jun 28-Jul 3, 1998
54. Farnsworth A et al. Women first: a study of the effects of treatment in women+HIV-infected with combination melfinavir, saquinavir, stavudine, and lamivudine [abstract]. 12th World AIDS Conference, Geneva June 28-Jul 3, 1998
55. Opravil M, The Spice Study Team. Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals [abstract no. 394b]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998
56. Mellors J, Lederman M, Haas D, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (PIs) [abstract no. 4]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998
57. Hecht FM, Smith D, Cooper D, et al. Treatment of primary HIV infection with nelfinavir, zidovudine, and lamivudine [abstract]. 12th World AIDS Conference, Geneva Jun 28-Jul 3, 1998
58. Conant M, Markowitz M, Hurley A, et al. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept as monotherapy in HIV positive patients [abstract]. 11th International Conference on AIDS 1996 Jul 7; 1: 286-7
59. Moyle G, Youle M, Chapman S, et al. A phase II dose escalation study of the agouron protease inhibitor AG 1343 [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Sep 17 Program Addendum: 8
60. Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor AG1343 [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Sep 17 Program Addendum: 8
61. Youle M, Moyle G, Chapman S, et al. Phase I/II study of AG1343, a novel HIV protease inhibitor [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 369C
62. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51: 701-12
63. Moyle GJ, Gazzard BG, Cooper DA. Antiretroviral therapy for HIV infection: a knowledge-based approach to drug selection and use. Drugs 1998 Mar: 55: 383-404
64. Saag M, Knowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate) in triple combination therapy [abstract]. 17th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28: 261-2
65. Saag M, Gersten M, Chang Y, et al. Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT (Rm) (nelfinavir mesylate) in combination with zidovudine and lamivudine [abstract]. Clin Infect Dis 1997 Aug; 25: 396
66. Peterkin J, Chapman S, Conant M, et al. Randomized phase II studies of VIRACEPT (Rm), an HIV protease inhibitor, given as monotherapy and in combination with stavudine (d4T) [abstract]. Antiviral Res 1996 Apr; 30: 19
67. Martel L, Valentine M, Ferguson L, et al. Virologic and CD4 response to treatment with nelfinavir in therapy experienced but protease inhibitor naive HIV-infected children [abstract no. 233]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998
68. Sension M, et al. Safety and efficacy of BID dosing of Viracept (nelfinavir mesylate) with 2 NRTI's [abstract]. 12th World AIDS Conference, Geneva 1998 Jun 28-Jul 3
69. Skowron G et al. Stavudine (d4T). nelfinavir (NFV) and nevirapine (NVP): suppression of HIV-1 RNA to fewer than 50 copies/ml during 5 months of therapy [abstract]. 12th World AIDS Conference, Geneva 1998 Jun 28-Jul 3
70. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997 May 8; 387: 188-91
71. Yu G. Viral load levels during treatment with Viracept combination treatment as predictor of response and guidance for treatmennt choice strategy [abstract]. 12th World AIDS Conference, Geneva Jun 28-Jul 3, 1998
72. Zorilla C, Clark R, Currier J, et al. Women first: a study in HIV positive women of quadruple therapy: nelfinavir (NFV), saquinavir (SQV), Stavudine (d4T) and lamivudine (3TC) [poster]. 5th Conference on Retroviruses and Opportunistic Infections; Chicago 1998 1-5 Feb
73. Eron J, Haubrich R, Richman D, et al. Preliminary assessment of 141W94 in combination with other protease inhibitors [abstract no. 6]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998
74. Gallant JE, Heath-Chiozzi M, Raines C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy [poster]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 1-5 Feb: 394a
75. Kravcik S, Seguin I, Sahai J, et al. Long term follow-up of a cohort of HIV infected persons treated with nelfinavir and saquinavir SGC in combination [abstract]. Can J Infect Dis 1997 Mar-Apr; 8 Suppl. A: 45A
76. Becker MI, Wilson D, Yuen N, et al. An expanded access program with VIRACEPT (nelfinavir mesylate) [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28: 262
77. Razecca K, et al. The treatment (TX) of nelfinavir (NFV) induced diarrhea ( NFVID) [abstract]. 12th World AIDS Conference, Geneva Jun 28-Jul 3, 1998
78. Hawkins et al. Nelfinavir-associated diarrhea is manageable with nonprescription medications [abstract]. 12th World AIDS Conference, Geneva Jun 28-Jul 3, 1998
79. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [letter]. Ann Intern Med 1997 Nov 15; 127: 947
80. Dong BJ, Gruta C, Legg J, et al. Diabetes and use of protease inhibitors [abstract no 416]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 Feb 1-5
81. Protease inhibitor class labeling warning for diabetes, hyperglycemia [abstract]. FDC Pink 1997 Jun 16; 59: 5-6
82. Roth VR, Angel JB, Kravcik S. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors [abstract no. 411]. Program and Abstracts 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998: 156
83. Mann M, Piazza-Hepp T, Koller E, et al. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA summary [abstract]. 5th Conference on Retroviruses and Opportunistic Infections Chicago 1998 Feb 1-5: 415
84. Hengel RL, Geary JAM, Vuchetich MA, et al. Multiple symmetrical lipomatosis associated with protease inhibitor therapy [abstract no. 407]. Program and Abstracts 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998: 156
85. Rosenberg HE,. Mulder J, Sepkowitz KA, et al. 'Protease paunch' in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation [abstract no. 408]. Program and Abstracts 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998: 156
86. Lo J, Mulligan K, Tai VW, et al. Buffalo hump in HIV-infected patients on antiretroviral therapy [abstract no. 409]. Program and Abstracts 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998: 156
87. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PI's) [abstract no. 410]. Program and Abstracts 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998: 156
88. Dube M, et al. Protease inhibitor-associated hyperglycemia: results of switching from indinavir to nelfinavir [abstract]. 12th World AIDS Conference, Geneva Jun 28-Jul 3, 1998
89. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996 Feb 15; 334 (7): 426-31
90. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997 Sept 11; 337 (11): 725-33
91. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995 Jan 27; 267: 483-9
92. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996 March 15; 271: 1582-6
93. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14
94. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997 Nov 14; 278: 1295-300
95. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanisms of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998 Jan-Feb; 20: 2-25
96. Lewis II JS, Terriff CM, Coulston DR, et al. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther 1997 Mar-Apr; 19: 187-214
97. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev 1997-1998: 145-85
98. Deeks SG, Smith M, Holodniy M. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997 Jan 8; 277: 145-53